韩国低风险甲状腺微小乳头状癌患者主动监测与立即手术的成本最小化分析:基于MAeSTro研究
基于MAeSTro多中心前瞻性队列的模拟模型,比较低风险甲状腺微小乳头状癌主动监测与立即手术的累积成本。主动监测初始成本为肺叶切除术的1/5.6,3%贴现率下10年累积成本相近(2545美元 vs 3045美元),长期随访中立即手术可能更经济。
要点
- 主动监测初始成本比肺叶切除术低5.6倍(不考虑左甲状腺素治疗)。
- 3%贴现率下10年累积成本主动监测2545美元 vs 肺叶切除术3045美元,两者相近。
- 长期随访中立即手术估计比主动监测更经济,但需谨慎解读。
核心结论
- 考虑直接和间接成本,低风险PTMC患者主动监测与立即手术的10年累积成本相近。
- 对于预期寿命较长的患者,长期随访中手术可能更经济。
- 长期随访结果需谨慎解读,并需考虑各国医疗体系与环境。
研究设计与样本
- 基于MAeSTro多中心前瞻性队列研究的假设模型模拟。
- 从诊断到治疗决策及随访10年及更长时间,估算直接和间接成本。
- 场景包括主动监测、因改变主意从主动监测转为手术、肺叶切除术(分为用与不用左甲状腺素)。
- 使用不同贴现率进行敏感性分析以处理未来时间成本的不确定性。
- 参考香港、美国和日本既往研究进行成本比较。
主要发现
- 主动监测初始成本估计比肺叶切除术(无论是否用左甲状腺素)低5.6倍。
- 3%贴现率下,主动监测10年累积成本为2545美元,肺叶切除术(无论是否用左甲状腺素)为3045美元,两者相近。
- 长期随访中,立即手术估计比主动监测更经济。
- 两种管理方式的成本在香港相近,但在美国和日本差异显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 长期随访结果需谨慎解读。
- 成本比较可能受各国国家医疗保险覆盖范围和随访期间甲状腺超声间隔的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Active surveillance (AS) has been established as an alternative to immediate surgery for low-risk papillary thyroid microcarcinoma (PTMC). Nonetheless, it remains difficult to decide between AS and immediate surgery, since limited objective evidence exists regarding risks and benefits. The aim of study is to compare the cumulative costs of AS and immediate surgery. Methods: To estimate cumulative costs, a hypothetical model is simulated based on the Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Micro-Carcinoma (MAeSTro) study, a multicenter prospective cohort study of AS for PTMC. Direct and indirect costs are estimated from diagnosis to the treatment decision and follow-up for 10 years and a longer period. In the case of the scenarios, AS, AS to surgery due to changing their mind, and lobectomy (analyzed regardless of levothyroxine [LT4] treatment, as well as subdivided into lobectomy/LT4[-] and lobectomy/LT4[+]) are considered. A sensitivity analysis is performed using different discount rates to address uncertainties in future time costs. To compare the cumulative costs, we referred to previous research conducted in Hong Kong, the United States, and Japan. Results: The initial cost of AS is estimated to be 5.6 times lower than that of lobectomy (regardless of LT4 use), while the 10-year cumulative costs of AS ($2545) and lobectomy regardless of LT4 ($3045) are similar under a discount rate of 3%. However, in the long-term follow-up period, immediate surgery is going to be estimated more economical than AS. The costs of the two management approaches are similar in Hong Kong, but substantially different in the United States and Japan, implying that it could be affected by each country's national health insurance coverage and the thyroid ultrasound interval during follow-up. Conclusion: Considering both direct and indirect costs, the cumulative costs of AS and immediate surgery in low-risk PTMC patients are similar during 10 years, and surgery could be more economical for patients with a life expectancy in long-term follow-up. However, careful interpretation is needed for long-term follow-up and the country's health care system and environment. Nevertheless, considering the representative protocols and objective costs in South Korea, it is expected to be a key to suggest the appropriate treatment for PTMC patients.
引用
- Kim K, Choi JY, Kim SJ, et al. Active Surveillance Versus Immediate Surgery for Low-Risk Papillary Thyroid Microcarcinoma Patients in South Korea: A Cost-Minimization Analysis from the MAeSTro Study. Thyroid. 2022. PMID: 35570657. doi:10.1089/thy.2021.0679
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。